“The decrease was primarily due to: ● Decrease in other research expenses of $15,910,400 primarily associated with the wind-down of the 302 and 304 studies in 2025; ● Decrease in stock-based compensation expense of $3,398,300; ● Decrease in manufacturing and drug storage costs of $286,200; ● Increase in costs of $2,717,900 associated with the acquisitions of Sepranolone and NDV-01 in the first quarter of 2025 offset with a decrease of 302 and 304 study expenses due to the wind-down of these studies; and ● Increase in compensation expense of $508,200 due to an increase in research and development employees and their related bonuses.”
“If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of product candidates from government-funded healthcare programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations.”
“The increase in constant currency total and same-store pawn receivables is primarily due to increasing demand for pawn loans and larger loan sizes, driven in part by higher gold prices and a slightly increased mix of higher value jewelry loans.”